 |
|
New vaccine may give long-term defense against deadly bird flu and its variant forms
April 18, 2008A new vaccine under development may provide protection against highly pathogenic bird flu and its evolving forms, according to researchers at Purdue University and the Centers for Disease Control and Prevention who discovered the new preventative drug and have tested it in mice.
Unlike traditional influenza vaccines, the new vaccine could be produced quickly and stored for long periods in preparation for a pandemic of dangerous disease-causing avian influenza - H5N1 - and its variants, said Suresh Mittal, a Purdue virologist. In an earlier study with mice, he and his colleagues found that the vaccine protected against H5N1 for a year or longer. Because the studies have only been done in mice, it's not yet known whether the same results will be obtained in humans.
"We want to have a vaccine that can be stored in advance and have the potential to provide protection for a period of time until we can change the vaccine to match the latest form of avian influenza," Mittal said. "The combination of flu genes that we've used to produce the vaccine, I think, will provide that capability."
The importance of having a long-lasting, broadly protective vaccine is that it would give some cross-protection against new viruses with pandemic potential caused by mutations in currently circulating H5N1 viruses. This would give scientists time to develop a better vaccine that would match the latest form of the bird flu.
Mittal and his colleagues, including Suryaprakash Sambhara, the CDC principal investigator on the project, report their findings on the vaccine in the April 15 issue of The Journal of Infectious Diseases. In the December issue of Clinical Pharmacology and Therapeutics, Mittal, Sambhara and their collaborators published their findings of the long-lasting capabilities of the vaccine.
"In humans we want a vaccine to be fully effective for at least a year," said Mittal, a professor of comparative pathobiology. "How long it will last in humans, we don't know yet."
To produce the new vaccine, the scientists used a mutated common cold virus, known as an adenovirus, as a delivery system for important genes from two types of the H5N1 avian influenza. The adenovirus is incapable of multiplying and so cannot cause illness to people. By using the adenovirus vector technology, a couple of problems with existing vaccines used to fight annual flu outbreaks are solved.
Problems with current influenza vaccines include that they are made from eggs, a process that can take as long as six months. The vaccine Mittal and his research team has developed isn't grown in eggs, making vaccine production much faster.
Additionally it would be difficult under normal conditions to produce the hundreds of millions of doses needed to protect everyone at risk for highly pathogenic forms of bird flu. With the beginning of a pandemic, since H5N1 decimates poultry populations, the egg supply needed to produce vaccines would be drastically cut.
The new vaccine uses an adjuvant, molecules added to the vaccine that stimulate the body's immune system, so that lower doses of the vaccine can be used. The adjuvant also allows the vaccine to be stockpiled so more people can be vaccinated, and it helps the vaccine protect against variant forms of the H5N1. The only FDA-approved H5N1 vaccine protects against only that specific strain of flu and only works in about 60 percent of those immunized with a high dose.
"Adenoviral vector-based pandemic vaccines are an attractive option for developing countries where egg-independent cell-based vaccine technologies for other vaccines already are available," Sambhara said. "Since this process is already in place, our vaccine could be produced locally at an affordable price."
Since H5N1 has been known, it has changed so that there are now two main subgroups, called clades. Within one of the clades, five subclades have emerged. This has complicated the task of developing a "perfect match" vaccine for the highly pathogenic bird flu. Other avian influenza viruses exist, but they have not proved to be as lethal to humans or other animals as has H5N1.
Influenza viruses are classified according to the combination of two types of proteins found on the virus cell surface. Different combinations of the 16 types of hemagglutinin (H) protein and nine types of neuraminidase (N) protein form a large number of influenza viruses for which birds are the natural hosts.
New, often more dangerous flu strains develop when the H and N combinations change and combine with other genes from circulating influenza viruses. When the genes of a human or swine influenza mix with an avian variety, a highly pathogenic human flu likely will result, Mittal said.
The first bird-to-human H5N1 case was recorded in 1997 in Hong Kong. The deadly virus has been documented in more than 60 countries, according to the World Health Organization (WHO). Though it mainly has struck wild birds and poultry, there have been more than 300 human cases in 14 countries in the past decade with a 60 percent fatality rate. Most of the human cases have occurred in people who live and work closely with their poultry, but a few cases have been documented of the disease spreading from person to person.
In a typical case, WHO this week reported the most recent fatality - the death of a 30-year-old Egyptian woman who became ill on April 2 after handling sick birds. She did not respond to the antiviral treatment Tamiflu, which can be given after contact with a flu carrier.
The next step in the bird flu vaccine project will be to test the vaccine on new viruses that are appearing, Mittal said.
The scientific team's vaccine work is being developed by PaxVax Inc., which has licensed the technology. Mittal is a scientific adviser for the company but has no financial stake in the commercial development of the vaccine, nor do his colleagues.
National Institute of Allergy and Infectious Diseases and the CDC's National Center for Infectious Diseases and National Vaccine Program provided funding for the study.
The other researchers involved with The Journal of Infectious Diseases study were paper co-lead researcher Mary Hoelscher, postdoctoral researcher Sanjay Garg, research scientists Vic Veguilla and Yumi Matsuoka, and principal investigators Jacqueline Katz and Ruben Donis, all of the CDC; and co-lead researcher Neetu Singh, postdoctoral researcher Lakshmi Jayashankar, and graduate student Aseem Pandey, all of Mittal's Purdue laboratory.
The other researchers involved with the Clinical Pharmacology and Therapeutics study were Hoelscher, Garg, Veguilla, Katz and Xuihua Lu of the CDC; and Singh and Jayashankar of Purdue. Hoelscher and Jayashankar were equal contributors for this study.
Purdue University
The importance of having a long-lasting, broadly protective vaccine is that it would give some cross-protection against new viruses with pandemic potential caused by mutations in currently circulating H5N1 viruses. This would give scientists time to develop a better vaccine that would match the latest form of the bird flu.
Mittal and his colleagues, including Suryaprakash Sambhara, the CDC principal investigator on the project, report their findings on the vaccine in the April 15 issue of The Journal of Infectious Diseases. In the December issue of Clinical Pharmacology and Therapeutics, Mittal, Sambhara and their collaborators published their findings of the long-lasting capabilities of the vaccine.
"In humans we want a vaccine to be fully effective for at least a year," said Mittal, a professor of comparative pathobiology. "How long it will last in humans, we don't know yet."
To produce the new vaccine, the scientists used a mutated common cold virus, known as an adenovirus, as a delivery system for important genes from two types of the H5N1 avian influenza. The adenovirus is incapable of multiplying and so cannot cause illness to people. By using the adenovirus vector technology, a couple of problems with existing vaccines used to fight annual flu outbreaks are solved.
Problems with current influenza vaccines include that they are made from eggs, a process that can take as long as six months. The vaccine Mittal and his research team has developed isn't grown in eggs, making vaccine production much faster.
Additionally it would be difficult under normal conditions to produce the hundreds of millions of doses needed to protect everyone at risk for highly pathogenic forms of bird flu. With the beginning of a pandemic, since H5N1 decimates poultry populations, the egg supply needed to produce vaccines would be drastically cut.
The new vaccine uses an adjuvant, molecules added to the vaccine that stimulate the body's immune system, so that lower doses of the vaccine can be used. The adjuvant also allows the vaccine to be stockpiled so more people can be vaccinated, and it helps the vaccine protect against variant forms of the H5N1. The only FDA-approved H5N1 vaccine protects against only that specific strain of flu and only works in about 60 percent of those immunized with a high dose.
"Adenoviral vector-based pandemic vaccines are an attractive option for developing countries where egg-independent cell-based vaccine technologies for other vaccines already are available," Sambhara said. "Since this process is already in place, our vaccine could be produced locally at an affordable price."
Since H5N1 has been known, it has changed so that there are now two main subgroups, called clades. Within one of the clades, five subclades have emerged. This has complicated the task of developing a "perfect match" vaccine for the highly pathogenic bird flu. Other avian influenza viruses exist, but they have not proved to be as lethal to humans or other animals as has H5N1.
Influenza viruses are classified according to the combination of two types of proteins found on the virus cell surface. Different combinations of the 16 types of hemagglutinin (H) protein and nine types of neuraminidase (N) protein form a large number of influenza viruses for which birds are the natural hosts.
New, often more dangerous flu strains develop when the H and N combinations change and combine with other genes from circulating influenza viruses. When the genes of a human or swine influenza mix with an avian variety, a highly pathogenic human flu likely will result, Mittal said.
The first bird-to-human H5N1 case was recorded in 1997 in Hong Kong. The deadly virus has been documented in more than 60 countries, according to the World Health Organization (WHO). Though it mainly has struck wild birds and poultry, there have been more than 300 human cases in 14 countries in the past decade with a 60 percent fatality rate. Most of the human cases have occurred in people who live and work closely with their poultry, but a few cases have been documented of the disease spreading from person to person.
In a typical case, WHO this week reported the most recent fatality - the death of a 30-year-old Egyptian woman who became ill on April 2 after handling sick birds. She did not respond to the antiviral treatment Tamiflu, which can be given after contact with a flu carrier.
The next step in the bird flu vaccine project will be to test the vaccine on new viruses that are appearing, Mittal said.
The scientific team's vaccine work is being developed by PaxVax Inc., which has licensed the technology. Mittal is a scientific adviser for the company but has no financial stake in the commercial development of the vaccine, nor do his colleagues.
National Institute of Allergy and Infectious Diseases and the CDC's National Center for Infectious Diseases and National Vaccine Program provided funding for the study.
The other researchers involved with The Journal of Infectious Diseases study were paper co-lead researcher Mary Hoelscher, postdoctoral researcher Sanjay Garg, research scientists Vic Veguilla and Yumi Matsuoka, and principal investigators Jacqueline Katz and Ruben Donis, all of the CDC; and co-lead researcher Neetu Singh, postdoctoral researcher Lakshmi Jayashankar, and graduate student Aseem Pandey, all of Mittal's Purdue laboratory.
The other researchers involved with the Clinical Pharmacology and Therapeutics study were Hoelscher, Garg, Veguilla, Katz and Xuihua Lu of the CDC; and Singh and Jayashankar of Purdue. Hoelscher and Jayashankar were equal contributors for this study.
Purdue University
Influenza Current Events and Influenza News RSSRethinking Who Should Be Considered 'Essential' During a Pandemic Flu Outbreak
Not only are doctors, nurses, and firefighters essential during a severe pandemic influenza outbreak. So, too, are truck drivers, communications personnel, and utility workers.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.
Scientists working to protect NI from Bird Flu
Queen's scientists are involved in two international projects aimed to protect Northern Ireland's agri-food industry from Bird Flu and African Swine Fever, a disease which kills pigs.
Colds and flu cut by one-third in study of Canada's top cold fighter in vaccinated seniors
A winter free from colds and flu? Not yet. But a new study offers new evidence that Canada's top cold and flu-fighting product provides significant help.
Previous claims of siRNA therapeutic effects called into question by report in human gene therapy
The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response, according to a paper in the September 2008 issue (Volume 19, Number 9) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.
Substance found in fruits and vegetables reduces likelihood of the flu
Mice given quercetin, a naturally occurring substance found in fruits and vegetables, were less likely to contract the flu, according to a study published by The American Physiological Society. The study also found that stressful exercise increased the susceptibility of mice to the flu, but quercetin canceled out that negative effect.
Flu shot does not reduce risk of death
The widely-held perception that the influenza vaccination reduces overall mortality risk in the elderly does not withstand careful scrutiny, according to researchers in Alberta.
Discovery opens door for drugs to fight bird flu, other influenza epidemics
Researchers at Rutgers University and The University of Texas at Austin have reported a discovery that could help scientists develop drugs to fight the much-feared bird flu and other virulent strains of influenza.
UTMB researchers test new vaccine to fight multiple influenza strains
A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.
Bacterial pneumonia caused most deaths in 1918 influenza pandemic
The majority of deaths during the influenza pandemic of 1918-1919 were not caused by the influenza virus acting alone, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
More Influenza Current Events and Influenza News Articles
 | The Great Influenza: The Epic Story of the Deadliest Plague In History by John M. Barry In the winter of 1918, at the height of WWI, history’s most lethal influenza virus erupted in an army camp in Kansas, moved east with American troops, then exploded, killing as many as 100 million people worldwide. It killed more people in twenty-four weeks than AIDS has killed in twenty-four years, more in a year than the Black Death killed in a century. But this was not the Middle Ages, and... |
| The Great Influenza (The Epic Story of the Deadliest Plague in History) | |
 | Pandemic Influenza: Emergency Planning and Community Preparedness “... an amazing resource ... Dr. Ryan has assembled some of the best experts in the field to guide you in understanding the threat of pandemic influenza and how it can affect you and the people you are responsible for. ...” From the foreword by Lynn A. Slepski, Captain, United States Public Health Service No one is immune to the potential devastation of a mass pandemic influenza... |
 | A Warning Shot: Influenza and the 2004 Flu Vaccine by Timothy Brookes A Warning Shot is a story of paradoxes. It is about the failure of government regulatory oversight as well as the heroic efforts of public health officials to respond to the crisis. It is the story of catastrophic production failure at one company and the work of others to fill the void. It is a tale about the failure of national leadership to protect our nation’s vaccine supply at a time when... |
 | Influenza 1918 (The American Experience) by Lynette Iezzoni |
 | Influenza Virology: Current Topics by Yoshihiro Kawaoka |
| Influenza (Deadly Diseases and Epidemics) by Donald Emmeluth | |
 | Fever of War: The Influenza Epidemic in the U.S. Army during World War I by Carol Byerly "Fever of War adds an important dimension to knowled of the influenza pandemic of 1918-1919."David Killingray, Goldsmiths College, University of London It is a must read for anyone interested in military or health care history.—Nursing History ReviewFever of War is well written, meticulously researched, and poses much food for thought.&$151;On Point "Prof. Byerly's superb research and... |
 | Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program Planning for an influenza pandemic, whether it occurs in the near or distant future, will need to take into account many constantly evolving factors. The Institute of Medicine (IOM) Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic was asked by the Department of Health and Human Services, (DHHS) to consider best practices and policies for providing antiviral... |
 | Flu: A Social History of Influenza by Tom Quinn This fascinating book explores the havoc caused by the world's most deadly virus - and the destruction left behind in its... |
| © 2008 BrightSurf.com |